ClinicalTrials.gg
Not yet recruitingNCT07642700Updated Jun 11, 2026

GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET

An observational study in Chronic Endometritis, sponsored by Guoxia Yang. Not yet recruiting. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Guoxia Yang · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Women with PCE represent a treatment-resistant phenotype in whom the endometrial inflammatory and immune status remains abnormal despite antibiotic therapy. GnRH agonist pretreatment may be most beneficial in endometrial phenotypes marked by persistent or residual inflammatory impairment rather than in all frozen embryo transfer populations.We therefore conducted a single-center prospective cohort study to investigate whether GnRH-HRT, compared with non-GnRH-based preparations, improve clinical pregnancy and live birth in women with PCE undergoing FET,

02

Conditions studied

  • Chronic Endometritis

Browse trials for

03

In context

Endometritis

50 studies on the registry are indexed under Endometritis; 11 are open to participants now.

Browse Endometritis studies →

Lead sponsor

This is the only study on the registry with Guoxia Yang as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

This prospective cohort study enrolls infertile patients diagnosed with persistent chronic endometritis who receive FET in reproductive center. Subjects are allocated into two groups: down-regulation endometrial preparation group and conventional artificial cycle or natural cycle group. We compare implantation, clinical pregnancy, miscarriage and live birth rates between two regimens.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 20-40 years; confirmed persistent chronic endometritis (PCE) via hysteroscopy plus CD138 immunohistochemistry, defined as positive endometrial pathology after two-course antibiotic treatment for CE.
  • Frozen-thawed embryo transfer (FET) with available transferable cleavage-stage or blastocyst embryos from IVF/ICSI cycles.
  • No acute pelvic infection at enrollment; ≥1 month elapsed after completion of last antibiotic therapy for endometritis.
  • Normal uterine cavity except for inflammatory changes of PCE; no severe uterine malformation or severe intrauterine adhesion requiring surgical intervention.
  • Voluntarily sign and complete full follow-up of pregnancy outcomes

Exclusion criteria

Exclusion Criteria:

  • History of pelvic tuberculosis, intrauterine adhesions, submucous uterine myoma or endometrial polyp before FET
  • Uncontrolled systemic endocrine disorders, diseases (APS, SLE), severe hepatic/renal/cardiopulmonary dysfunction.
  • Known allergy to GnRH agonist for down-regulation regimen; prior long-acting GnRH-a intolerance.
  • Recent use of , long-term or drugs interfering endometrial development within 3 months before enrollment.
  • Lost to follow-up or plan to abandon embryo transfer after enrollment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • GnRH/HRT

    PCE patients with GnRH agonist pretreatment combined with hormone replacement therapy (GnRH-HRT) endometrial preparation

    Drug: GnRH agonist plus estrogen-progesterone for endometrial preparation

  • non-GnRH-HRT

    PCE patients with non-GnRH-HRT regimens (HRT alone or natural cycle, NC),

    Drug: Conventional estrogen-progesterone artificial cycle for endometrial preparation

Interventions

  • DrugConventional estrogen-progesterone artificial cycle for endometrial preparation

    No GnRH-a down-regulation. Oral estrogen is initiated directly on early menstrual cycle, followed by progesterone transformation to prepare endometrium for FET in patients with persistent chronic endometritis.

  • DrugGnRH agonist plus estrogen-progesterone for endometrial preparation

    Long-acting GnRH agonist is administered on day 2-3 of menstruation for pituitary down-regulation. After satisfactory hormonal suppression, sequential oral estrogen and progesterone are used to prepare endometrium before frozen embryo transfer in patients with persistent chronic endometritis.

06

What researchers measure

Primary outcomes

  1. Clinical pregnancy rate

    Clinical pregnancy was defined as the visualization of at least one gestational sac on transvaginal ultrasonography at 6-7 weeks of gestation

    Time frame: 6-7 weeks

Secondary outcomes

  1. miscarriage rate

    Miscarriage rate was defined as the proportion of clinical pregnancies ending in spontaneous pregnancy loss before 24 gestational weeks. Early miscarriage was defined as pregnancy loss occurring before 12 weeks of gestation.

    Time frame: 24 weeks

  2. Live birth rate

    Live birth was defined as the delivery of at least one live-born infant at ≥24 weeks of gestation.

    Time frame: 37 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 11, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07642700
Lead sponsor
Guoxia Yang
Responsible party
Guoxia Yang (Associate Chief Physician, Reproductive Medicine Department, First Affiliated Hospital, Sun Yat-Sen University) — Sponsor-investigator
First posted
Jun 11, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Jun 11, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion